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Summary. Patients with diverticulosis who develop persistent abdominal pain, bloating and changes in bow-
el habits not associated with overt inflammation may have symptomatic uncomplicated diverticular disease 
(SUDD). The severity and frequency of SUDD symptoms may have an impact on daily activities and severely 
affect quality of life. Effective management of SUDD should follow a three part strategy: divert, tackle and 
maintain. Divert to make the correct diagnosis: several symptoms of SUDD are common to other conditions 
that require different therapeutic approaches. However, several key differences should be used to diagnose 
SUDD. Pain in SUDD is normally in the iliac fossa, persistent, often lasting more than 24 hrs, and is not re-
lieved by bowel movement, as is often the case with irritable bowel syndrome. Another difference is in the tim-
ing: the prevalence of SUDD increases with age, and patients under the age of 40 years are less likely to have 
diverticula. It is useful to establish whether a patient has diverticulosis, especially if the patient is relatively 
young; lack of diverticula excludes SUDD. Cross-sectional imaging is indicated; however, recent archival im-
age data or ultrasonography may be useful alternatives. Laboratory tests should be ordered to exclude overt 
inflammation. Once the diagnosis of SUDD is made, the patient should receive effective therapy to tackle the 
condition. This should include dietary fibre supplementation and cyclic treatment with rifaximin 400 mg twice 
daily for 7 days per month. Once symptom control is achieved, it should be maintained by continuing therapy 
for at least 12 months. (www.actabiomedica.it)
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F o c u s  o n
Terminology 
Diverticulosis: the presence of diverticula 
Diverticular disease: any symptomatic condition in-
volving diverticula 
Diverticulitis: diverticular macro inflammation with 
local pain symptoms
Complicated diverticulitis: abscesses, fistulae, ob-
structions or perforations 
Symptomatic uncomplicated diverticular disease: 
diverticula with persistent localised pain and diar-
rhoea/constipation, without macroscopic inflamma-
tion.
Introduction
Diagnosing the cause of abdominal pain can be 
challenging (1), especially due to the large number of 
conditions presenting with this symptom (2). Clinicians 
should be vigilant to the possibility of colorectal cancer 
in patients with this clinical scenario, due to its increas-
ing incidence even among younger patients (3, 4). Ab-
dominal pain can result from functional- or structural 
gastrointestinal (GI) disorders. Functional GI disorders 
include idiopathic bowel disorders thought to involve 
visceral hypersensitivity, visceral nociceptors and/or 
impaired gastrointestinal motility: Irritable bowel syn-
drome is the major entity in this group (5). In contrast, 
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structural GI disorders have an established physical 
cause such as an infection, neoplastic disease, autoim-
mune reaction or inflammation; they include various 
forms of colitis (e.g., infectious or ulcerative colitis, 
Crohn’s disease) and diverticular diseases.
Diverticular disease (DD) is prevalent in western 
and industrialized societies, and appears to be associ-
ated with the low fibre content in the diet (6, 7). DD 
accounts for substantial part of burden of digestive dis-
eases (8-11).
Diverticula are outpouchings of intestinal colonic 
mucosal and submucosal layers that protrude through 
weak points in the colon wall, typically at the points 
where the vasa rectae traverse. The incidence of this 
condition, known as diverticulosis, is high, increases 
with age, and in the great majority of cases remains 
asymptomatic (12). However, approximately 20% of 
patients will develop symptoms and complications 
(13). The term diverticular disease (DD) refers to any 
condition in which the presence of diverticula is as-
sociated with symptoms. Infection/macroscopic in-
flammation associated with a diverticulum occurs in 
approximately 15% of symptomatic patients and may 
progress to extra-colonic infection/inflammation (di-
verticulitis). Diverticulitis is usually associated with 
abdominal pain, fever, tachycardia, and elevated mark-
ers for inflammation. Diverticulitis can lead to the 
formation of abscesses, fistulae, obstructions, perfora-
tions, or peritonitis, at which point it is known as com-
plicated diverticulitis (12). However, < 50% of patiens 
with acute diverticulitis, also those complicated with 
abscesses at CT scan, have the classical clinical triad of 
abdominal pain, fever and leucocytosis (14).
Patients with diverticulosis who develop a con-
stellation of persistent abdominal symptoms that in-
clude pain and changes in bowel habits that are not, 
however, associated with macroscopic inflammation or 
elevated systemic markers of inflammation, may have 
a condition known as symptomatic uncomplicated 
diverticular disease (SUDD). The diagnosis of symp-
toms of SUDD is complicated by the fact that several 
of its symptoms are common to other conditions that 
respond to different therapeutic approaches. There-
fore, correct diagnosis is critical to the management of 
SUDD (15).
SUDD
SUDD is defined as the concomitant presence 
of diverticula and symptoms of abdominal pain and 
bloating, bowel habit changes that include diarrhoea 
and constipation or a mixed bowel habit, in the ab-
sence of macroscopic inflammation (16, 17). The se-
verity and frequency of symptoms may have an impact 
on daily activities and severely affect quality of life 18); 
which can be assessed with the DD-specific DV-QoL 
survey (19).
Whereas the exact aetiology is not certain, a num-
ber of aspects of this condition have been investigated. 
Horgan et al. reported on a series of patients undergo-
ing surgery for SUDD (n = 930), in which three-quar-
ter of biopsies from patient who underwent resections 
showed signs of low-grade peridiverticular inflamma-
tion (20). It is suggested that chronic low-grade in-
flammation may provoke visceral hypersensitivity and 
changes in colonic motility. Patients with SUDD have 
a heightened sensitivity of isobaric distension (visceral 
hypersensitivity) compared to asymptomatic patients 
(21). Humes et al. assessed visceral sensitivity in pa-
tients with diverticular disease, reporting higher me-
dian mRNA levels of the neurokinin 1 receptor and 
TNF alpha in a group of 12 patients with symptomatic 
diverticular disease, compared to a group of 13 asymp-
tomatic patients. There was a significant correlation 
between barostat pain scores and neurokinin 1 recep-
tor expression (22). Simpson et al., sought to explain 
Figure 1. Classification of diverticular disease and frequency of 
the various forms
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the visceral hypersensitivity observed in patients with 
SUDD by assessing expression of neuropeptides in 
peridiverticular biopsies from 17 symptomatic and 15 
asymptomatic patients (23). Although histology was 
normal in both groups, there was significantly higher 
expression of the neuropeptides substance P, neuro-
peptide K, pituitary adenylate cyclase activating poly-
peptide, vasoactive intestinal polypeptide and galanin 
in the symptomatic group. Changes in neuromuscu-
lar function may influence colonic motility, causing 
changes in bowel habits, and may also influence per-
ception of abdominal pain (24). Bassotti et al. reported 
that patients with SUDD have abnormal motor activ-
ity and peristaltic action in the colon segments with 
diverticulosis, including a longer duration of rhythmic, 
low frequency contractile activity (25).
Another putative mechanism in SUDD is the ef-
fect on gut microbiota leading to chronic inflammation 
(26). The microbiota of patients with DD have reduced 
levels of bacterial with anti-inflammatory properties 
(e.g., Clostridium clusters IV and IX, Fusobacterium, 
and the Lactobacillaceae); these changes in microbiota 
are associated with mucosal immune activation (26). 
Such modifications in intestinal microbiota could 
result from faecal stasis due to the colonic dysmotil-
ity. The overgrowth of intestinal bacteria and chronic 
dysbiosis could promote inflammation thought the 
production of abnormal bacterial metabolites. A role 
for dysbiosis is also suggested by the efficacy of cyclic 
antibiotic treatment in controlling symptoms (27-31). 
Diagnosing SUDD
Diagnosing this condition is complicated by the 
fact that the symptoms may be difficult to distinguish 
from those of functional GI disorders such as irritable 
bowel syndrome (IBS) (17, 32) thus several key dif-
ferences should be used to differentiate between these 
conditions. 
First, the pain associated with SUDD is normally 
located in the iliac fossa (Figure 2), is more sustained, 
likely long-lasting or associated with history of pain 
lasting more than 24 hrs, and is not relieved by bowel 
movement, as is often the case with IBS (17, 33) (Ta-
ble 1).
The prevalence of SUDD increases with age (11), 
so that patients under the age of 40 years are less likely 
to have diverticula. Moreover, SUDD may follow a 
bout of acute of diverticulitis (34). 
Imaging 
Next, is useful to establish whether the patient 
has diverticulosis, especially if the patient is relatively 
young. The lack of diverticula would exclude SUDD. 
Gold standard methods include Computed Tomo-
graphic Colonography (CTC) or Colonoscopy (35). 
Although colonoscopy is the most widely used imag-
ing technique for assessing the colon, its accuracy in 
detecting colonic diverticula, in particular those lo-
cated in the sigmoid colon, is not superior to that of 
barium enema and CT colonography (35), so that a 
Figure 2. Most frequent location of abdominal pain associated 
with SUDD 
Table 1. Important pain characteristics differentiating SUDD 
from IBS. (modified from 17)
Pain characteristics  SUDD IBS
Diffuse/generalized no yes
Localised in left iliac fossa yes no
Relieved by passing stool or flatulence no yes
Wakes the patient at night yes no
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definite gold standard does not exist. The choice be-
tween these methods is therefore based on patient age, 
risk factors for polyps or cancer, clinical status, patient 
preference and local availability of the techniques (16). 
However, it is not practical to perform or repeat these 
examinations on all patients presenting with abdomi-
nal symptoms. Instead, we suggest that reference be 
made, where possible, to recent archival imagine data. 
When this is not available, recourse to ultrasonogra-
phy is a useful alternative (36). Advantages of ultra-
sonography include that it is less invasive, has a lower 
cost and may be more readily available and repeteable 
than conventional colonoscopy and colonography. It 
also avoids unnecessary exposure to ionising radiation, 
which is increasing important as the age of incidence 
for diverticular disease is decreasing (37) and real time 
examination allows to directly assess the exct site of 
pain of patients correlating this with the presence of 
underlying diverticula. So far, the accuracy of US in 
detecting left-sided diverticulosis has been assessed in 
only one prospective study that enrolled 60 patients 
and used colonoscopy as reference standard, showing 
a sensitivity of 85% with only 2 false positive results 
(38).
Biochemical markers
CRP is a general marker of inflammation that is 
useful for distinguishing patients with diverticulitis, or 
other overtly inflammatory condition. It is not specific 
for diverticular disease. Faecal calprotectin is a surro-
gate marker for intestinal inflammation. Calprotectin 
is a protein produced by neutrophils. Elevated levels in 
the faeces are indicative of inflammation of the intes-
tinal mucosa, including inflammation caused by IBD 
or bacterial infections. It is a relatively nonspecific test 
that can be positive not only for inflammatory bowel 
diseases, but also coeliac disease, infectious colitis, 
necrotizing enterocolitis, intestinal cystic fibrosis and 
colorectal cancer . Whereas, non-inflammatory con-
ditions like FAPS and IBS are negative. Reference 
ranges have been established, with cut-offs indicative 
of various conditions. The test can be used to measure 
disease activity status and response to therapy in IBD 
(39). It can inform differential diagnosis, as levels are 
only mildly elevated in patients with SUDD, but not 
in patients with IBS (40). Also in SUDD, levels cor-
relate with symptom severity (41).
Treatment with Rifaximin
Introduction of Rifaximin
Background on pharmacology and mechanism 
Rifaximin is a hydrophobic rifampicin derivative 
with negligible GI absorption. This property avoids 
systemic side effects and at the same time provides 
high faecal antibiotic concentrations (42). It inhibits 
gene transcription in both gram positive and gram 
negative bacterial by binding to the β-subunit of bac-
terial DNA-dependent RNA polymerase. Cyclic ad-
ministration of rifaximin combined with soluble fibre 
supplementation, is useful for treating SUDD. Cyclic 
treatment with rifaximin consists of administering 400 
mg twice daily for 7 days per month for at least 12 
months which alleviates symptoms, reduces the risk of 
recurrence or complications, and improves quality of 
life. (27-31, 43)
SUDD associated with dysbiosis and reduced lev-
el of beneficial bacteria (26). Rifaximin has a eubiotic 
effect on the intestinal microbiota (44) that may be 
accomplished through modulation of both the com-
position of gut microbiota and bacterial metabolism 
(45). Ponziani et al. conducted a molecular survey of 
intestinal bacteria before and after 10 days of rifaximin 
administration in 20 patients with a variety of condi-
tions. The main finding was the increase in beneficial 
Lactobacilli (45). Meanwhile, in a study of 15 patients 
with IBS not accompanied by constipation, rifaximin 
increased the presence of beneficial Faecalibacterium 
prausnitzii after 2 weeks of treatment (46). To date, the 
effect of rifaximin on the gut microbiota has not been 
assessed in large studies. 
Diagnosis and management of SUDD 29
Another potential mechanism is through anti-in-
flammatory effects in the gut mucosa (47). Rifaximin 
treatment is associated with a reduction in innate im-
mune effector cells in the colonic mucosa (Figure 3)
Moreover, bacteria are known to induce inflam-
mation by interacting with toll-like receptors that 
influence innate immunity and T-cell recruitment. 
Cianci et al. randomly assigned 40 consecutive asymp-
tomatic patients with uncomplicated DD to receive 
either rifaximin or placebo. Expression of Toll-like 
receptors 2 and 4, and intestinal homing of innate im-
mune cells were assessed in colonic mucosal biopsies 
at baseline and after 2 months of treatment. Rifaximin 
treatment normalised the distribution or toll-like re-
ceptor expression that is altered in patients with diver-
ticular disease (47). 
Putative additional mechanisms that may explain 
the observed clinical activity of rifaximin include de-
creasing bacterial adherence to epithelial cells, inhib-
iting their translocation across the GI epithelium, as 
well as activating the pregnane X receptor and thereby 
reducing levels of the proinflammatory transcription 
factor nuclear factor κB. 
Thus, rifaximin may work directly on gut bacteria 
and indirectly through host factors that may modify 
bacterial interactions with the intestinal mucosa and 
reduce inflammation (44).
Efficacy
Five randomized controlled studies have com-
pared rifaximin with placebo or fibre supplementation 
(27-31). A meta-analysis of these trials (n = 1660) 
revealed a 29.0% improvement in complete symp-
tom resolution with rifaximin (Rifaximin vs. control; 
95% CI 24.5-33.6; P<0.0001) (49), corresponding to 
a number needed to treat of 3 patients, in order to see 
a benefit in terms of complete resolution of symptoms. 
The largest trial was a prospective 12-month 
study in 968 patients with SUDD randomized to re-
ceive fibre supplementation (glucomannan 4 g/day) 
alone (n=346) or glucomannan plus daily rifaximin 
400 mg/day for 7 days every month (n=558) (29). 
The primary outcome was symptomatic relief at 12 
months, evaluated by symptom frequency and a global 
symptom score comprising upper and lower abdomi-
nal pain, bloating, tenesmus, diarrhoea, and abdominal 
tenderness. The secondary outcome was the incidence 
of complications, defined as development of diver-
ticulitis or rectal bleeding. Adding rifaximin result-
ed in fewer individual symptoms and a lower global 
symptom score (Figure 4). After 12 months, 56.5% of 
patients receiving glucomannan plus rifaximin were 
asymptomatic, compared to 29.2% with glucomannan 
alone (P<0.001). Incidence of AD or rectal bleeding 
was lower in the group receiving rifaximin (1.34% with 
rifaximin plus glucomannan vs. 3.22% with glucoman-
nan alone (P<0.05).
Tolerability of cyclic administration in patients with 
SUDD
Several long term studies have provided evidence 
that rifaximin is well tolerated, with adverse events 
with cyclic administration not significantly different 
from those in the control groups (49-51). Lanas et al. 
have reported potentially treatment-related adverse 
events during a 48-week study of 165 patients with re-
cent diverticulitis randomized to receive 3.5 g of fibre 
Figure 3. Rifaximin reduced mucosal CD103+ gamma-delta 
T cells, supporting the anti-inflammatory activity of rifaximin 
(figure from 48 modified)
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supplementation, with/without one week per month 
of rifaximin 400 mg twice daily (50).
Stallinger et al. conducted a non-interventional 
study of 1,054 adult patients with SUDD treated as 
outpatients with cyclic administration of rifaximin 
(51). Clinical visits were held at baseline and monthly 
thereafter for three months. During the study, 24 ad-
verse events were reported by 20 patients; six of these 
were related to the use of rifaximin, corresponding to 
an adverse event rate of 0.6%. Five events were GI ad-
verse events (flatulence/1 patient; abdominal pain/1 
patient; nausea/3 patients) and 1 was a skin rash. One 
reason for the low frequency of adverse events is that 
the alpha polymorphic form of rifaximin has negligible 
gut absorption and systemic availability (52).
Conclusions
SUDD is a multifactorial condition for which the 
correct diagnosis, although often difficult to obtain, pro-
vides the highest probability of successful management. 
To achieve this, we suggest combining a careful assess-
ment of the pain characteristics, with cross-sectional 
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(image adapted from 29)
Table 2. 
 Controls Treated
 (n = 88) (n = 77)
Patients with events* 6 8
Articular pain/discomfort 3 2
Increased hypercholesterolemia  2 0
Increased weight  1 1
Increased uricaemia  1 0
Increased glycemia 1 0
Cold/pulmonary phlegm  1 1
Itching  0 2
Anxiety  0 2
Diarrhoea at each administration  0 1
Increased triglycerides  0 1
Epididymitis 0 1
* Patients could report more than one event. (Adapted from 50)
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imaging to ascertain diverticulosis status and laboratory 
tests to exclude overt inflammation. The presence of a 
moderate level of faecal calprotectin may help to distin-
guish SUDD from non-inflammatory conditions such 
as IBS, which are completely negative, and inflamma-
tory conditions such as Crohn’s disease, ulcerative coli-
tis, and diverticulitis, which are clearly positive. 
Once correctly diagnosed, it is important to ad-
dress the condition with effective therapy. Fibre sup-
plementation plus cyclic treatment with rifaximin 
is well-tolerated in patients with SUDD and effec-
tive at controlling symptoms. Once symptom control 
has been achieved, it is important to consolidate and 
maintain these advances through cyclic administration 
of daily rifaximin for one week each month. 
On the basis of this we can conclude that the best 
approach for managing SUDD involves three basic 
steps: - Divert, that means approaching patients with 
abdominal pain in a different way, to make the cor-
rect diagnosis of SUDD; - Tackle the condition by 
providing the appropriate treatment, able to improve 
symptoms by acting on causes, and - Maintain, engag-
ing patients to let them understand the importance of 
cyclic treatment, to insure long-term recovery.
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